PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1596100
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1596100
Embolotherapy Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2030)
Market Overview
The global embolotherapy market is projected to generate approximately $4,018.0 million in revenue in 2024, with expectations to reach $6,447.1 million by 2030, reflecting a compound annual growth rate (CAGR) of 8.3% during the forecast period from 2025 to 2030. This growth is primarily driven by the increasing prevalence of chronic and lifestyle-associated diseases, advancements in medical technology, and favorable government initiatives aimed at improving public health. The rising demand for minimally invasive surgical procedures, coupled with substantial investments in healthcare infrastructure, is further propelling the market's expansion. Additionally, the availability of advanced embolic agents and devices, along with a growing focus on research and development, is enhancing the adoption of embolotherapy treatments worldwide.
Key Insights
The embolotherapy market is segmented by product into embolic agents and support devices. Embolic agents dominate the market, with revenue of $3,535.3 million in 2024, attributed to their increasing use in various interventional radiological procedures. Advancements in embolic agents, such as drug-eluting microspheres and radioactive yttrium-90 microspheres, are expected to drive the category's growth during the forecast period. Support devices, including microcatheters and guidewires, also play a crucial role in embolotherapy procedures, facilitating the precise delivery of embolic agents.
Procedurally, transcatheter arterial embolization (TAE) leads the market and is expected to be the fastest-growing category, with a CAGR of 8.9% during the forecast period. TAE is effective and well-tolerated in patients with ruptured hepatocellular carcinoma (HCC) and is preferred over transarterial chemoembolization (TACE) and transarterial radioembolization (TARE)/selective internal radiation therapy (SIRT). The increasing demand for minimally invasive procedures and the rapidly growing geriatric population are contributing to the growth of TAE procedures.
In terms of indications, cancer is the largest category in the embolotherapy market, projected to reach a value of $2,736.4 million in 2030. Embolization is extensively used for the treatment of various cancers, including kidney and liver cancers. The escalating rates of hepatocellular carcinoma (HCC) directly drive the demand for microspheres, as they are widely used for the treatment of HCC. As per the American Cancer Society, more than 850,000 diagnoses of liver cancer are registered around the world every year.
Geographically, North America leads the global embolotherapy market, attributed to the rising number of technological advancements, a strong healthcare ecosystem, a surging geriatric population, and the increasing prevalence of chronic diseases. The region's well-established healthcare infrastructure and favorable reimbursement policies further support market growth. The Asia-Pacific region is expected to witness significant growth during the forecast period, driven by improving healthcare infrastructure, increasing awareness about minimally invasive procedures, and a growing patient pool.
Technological advancements are a key trend in the embolotherapy market, with the development of biodegradable and multifunctional microspheres offering effective treatment options for hepatocellular carcinoma (HCC) by conjugating therapeutic radionuclides with chemotherapeutic agents. The introduction of advanced embolic agents, such as drug-eluting microspheres and calibrated microspheres for bland embolization, is enhancing the efficacy and safety of embolotherapy procedures.
The market is characterized by fragmentation, with several key players contributing to the competitive landscape. Major companies include Stryker Corporation, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Meril Life Sciences Pvt. Ltd., Medtronic Plc, Kaneka Corporation, Johnson & Johnson, Boston Scientific Corporation, BALT EXTRUSION SAS, Guerbet, and Abbott Laboratories. These companies are focusing on product launches, approvals, and strategic partnerships to strengthen their market positions. For instance, in April 2019, Guerbet received the Conformite Europeene (CE) mark for SeQure and DraKon microcatheters for peripheral embolization procedures. Moreover, in August 2019, Cook Medical LLC introduced the 2.6 Fr CXI support catheter, designed for use in super-selective or small-vessel anatomy during interventional and diagnostic procedures. The increasing focus on research and development, along with the rising awareness of cancer treatment, is driving the adoption of high-end embolotherapy treatments, presenting significant opportunities for market participants.
Table of Contents
Chapter 1. Research Background
- 1.1 Research Objectives
- 1.2 Market Definition
- 1.3 Analysis Period
- 1.4 Market Data Reporting Unit
1.4.1 Value
- 1.5 Market Size Breakdown by Segment
1.5.1 Market Segmentation by Product
1.5.2 Market Segmentation by Procedure
1.5.3 Market Segmentation by Indication
1.5.4 Market Segmentation by End User
1.5.5 Market Segmentation by Region
- 1.6 Key Stakeholders
Chapter 2. Research Methodology
- 2.1 Secondary Research
2.1.1 Paid
2.1.2 Unpaid
2.1.3 P&S Intelligence Database
- 2.2 Primary Research
2.2.1 Breakdown of Primary Research, by Region
2.2.2 Breakdown of Primary Research, by Industry Participant
2.2.3 Breakdown of Primary Research, by Company Type
- 2.3 Market Size Estimation
- 2.4 Data Triangulation
- 2.5 Currency Conversion Rates
Chapter 3. Executive Summary
Chapter 4. Introduction
- 4.1 Definition of Market Segments
4.1.1 By Product
- 4.1.1.1 Embolic agents
- 4.1.1.1.1 Microspheres
- 4.1.1.1.2 Bland PVA particles
- 4.1.1.1.3 Embolic coils
- 4.1.1.1.4 Liquid embolic agents
- 4.1.1.1.5 Embolic plug systems
- 4.1.1.1.6 Detachable balloons
- 4.1.1.2 Support devices
- 4.1.1.2.1 Microcatheters
- 4.1.1.2.2 Guidewires
4.1.2 By Procedure
- 4.1.2.1 TAE
- 4.1.2.2 TARE/SIRT
- 4.1.2.3 TACE
4.1.3 By Indication
- 4.1.3.1 Cancer
- 4.1.3.1.1 Kidney
- 4.1.3.1.2 Liver
- 4.1.3.1.3 Others
- 4.1.3.2 Peripheral vascular diseases
- 4.1.3.3 Neurological diseases
- 4.1.3.3.1 Cerebral aneurysms
- 4.1.3.3.2 Arteriovenous malformations and fistulas
- 4.1.3.4 Urological and nephrological disorders
- 4.1.3.5 Gastrointestinal disorders
4.1.4 By End User
- 4.1.4.1 Hospitals and clinics
- 4.1.4.2 ASCs
- 4.1.4.3 Others
- 4.2 Market Dynamics
4.2.1 Trends
- 4.2.1.1 Increasing number of product approvals and launches
- 4.2.1.2 Increasing number of acquisitions
- 4.2.1.3 Technological advancements in embolotherapy devices
4.2.2 Drivers
- 4.2.2.1 Increasing prevalence of chronic and lifestyle-associated diseases
- 4.2.2.2 Growing medical tourism sector
- 4.2.2.3 Rising healthcare expenditure and improving healthcare infrastructure
- 4.2.2.4 Surging patient preference for MISs
- 4.2.2.5 Impact analysis of drivers on market forecast
4.2.3 Restraints
- 4.2.3.1 Risks and challenges associated with embolization
- 4.2.3.2 Strong market positioning of alternative therapies
- 4.2.3.3 Dearth of skilled radiologists
- 4.2.3.4 Impact analysis of restraints on market forecast
4.2.4 Opportunities
- 4.2.4.1 Growing applications of liquid embolic agents
- 4.2.4.2 Untapped market in developing economies
- 4.2.4.3 Increasing adoption of image-guided procedures
- 4.3 Porter's Five Forces Analysis
Chapter 5. Global Market Size and Forecast
- 5.1 Global Market Size and Forecast
- 5.2 By Product
5.2.1 Embolic Agents Market, by Type
5.2.2 Embolotherapy Support Devices Market, by Type
- 5.3 By Procedure
5.3.1 TAE Market, By Product
- 5.3.1.1 TAE Embolic Agents Market, by Type
- 5.3.1.2 TAE Support Devices Market, by Type
5.3.2 TACE Market, By Product
- 5.3.2.1 TACE Embolic Agents Market, by Type
- 5.3.2.2 TACE Support Devices Market, by Type
5.3.3 TARE Market, By Product
- 5.3.3.1 TARE Embolic Agents Market, by Type
- 5.3.3.2 TARE Support Devices Market, by Type
- 5.4 By Indication
5.4.1 Embolotherapy Market for Cancer, by Type
- 5.4.1.1 Liver Cancer Embolotherapy Market, By Product
- 5.4.1.1.1 Liver Cancer Embolic Agents Market, by Type
- 5.4.1.2 Kidney Cancer Embolotherapy Market, By Product
- 5.4.1.2.1 Kidney Cancer Embolic Agents Market, by Type
- 5.4.1.3 Other Cancer Embolotherapy Market, By Product
- 5.4.1.3.1 Other Cancer Embolic Agents Market, by Type
5.4.2 Embolotherapy Market for Neurological Diseases, by Type
- 5.5 By End User
- 5.6 By Region
Chapter 6. North America Market Size and Forecast
- 6.1 By Product
6.1.1 Embolic Agents Market, by Type
6.1.2 Embolotherapy Support Devices Market, by Type
- 6.2 By Procedure
6.2.1 TAE Market, By Product
- 6.2.1.1 TAE Embolic Agents Market, by Type
- 6.2.1.2 TAE Support Devices Market, by Type
6.2.2 TACE Market, By Product
- 6.2.2.1 TACE Embolic Agents Market, by Type
- 6.2.2.2 TACE Support Devices Market, by Type
6.2.3 TARE Market, By Product
- 6.2.3.1 TARE Embolic Agents Market, by Type
- 6.2.3.2 TARE Support Devices Market, by Type
- 6.3 By Indication
6.3.1 Embolotherapy Market for Cancer, by Type
- 6.3.1.1 Liver Cancer Embolotherapy Market, By Product
- 6.3.1.1.1 Liver Cancer Embolic Agents Market, by Type
- 6.3.1.2 Kidney Cancer Embolotherapy Market, By Product
- 6.3.1.2.1 Kidney Cancer Embolic Agents Market, by Type
- 6.3.1.3 Other Cancer Embolotherapy Market, By Product
- 6.3.1.3.1 Other Cancer Embolic Agents Market, by Type
6.3.2 Embolotherapy Market for Neurological Diseases, by Type
- 6.4 By End User
- 6.5 By Country
6.5.1 U.S. Market Size and Forecast
- 6.5.1.1 By product
- 6.5.1.1.1 Embolic agents market, by type
- 6.5.1.1.2 Embolotherapy support devices market, by type
- 6.5.1.2 By procedure
- 6.5.1.2.1 TAE Market, By Product
- 6.5.1.2.1.1 TAE Embolic Agents Market, by Type
- 6.5.1.2.1.2 TAE Support Devices Market, by Type
- 6.5.1.2.2 TACE Market, By Product
- 6.5.1.2.2.1 TACE Embolic Agents Market, by Type
- 6.5.1.2.2.2 TACE Support Devices Market, by Type
- 6.5.1.2.3 TARE Market, By Product
- 6.5.1.2.3.1 TARE Embolic Agents Market, by Type
- 6.5.1.2.3.2 TARE Support Devices Market, by Type
- 6.5.1.2.1 TAE Market, By Product
- 6.5.1.3 By indication
- 6.5.1.3.1 Embolotherapy market for cancer, by type
- 6.5.1.3.2 Liver Cancer Embolotherapy Market, By Product
- 6.5.1.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 6.5.1.3.3 Kidney Cancer Embolotherapy Market, By Product
- 6.5.1.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 6.5.1.3.4 Other Cancer Embolotherapy Market, By Product
- 6.5.1.3.4.1 Other Cancer Embolic Agents Market, by Type
- 6.5.1.3.5 Embolotherapy market for neurological diseases, by type
- 6.5.1.4 By end user
6.5.2 Canada Market Size and Forecast
- 6.5.2.1 By product
- 6.5.2.1.1 Embolic agents' market, by type
- 6.5.2.1.2 Embolotherapy support devices market, by type
- 6.5.2.2 By procedure
- 6.5.2.2.1 TAE Market, By Product
- 6.5.2.2.1.1 TAE Embolic Agents Market, by Type
- 6.5.2.2.1.2 TAE Support Devices Market, by Type
- 6.5.2.2.2 TACE Market, By Product
- 6.5.2.2.2.1 TACE Embolic Agents Market, by Type
- 6.5.2.2.2.2 TACE Support Devices Market, by Type
- 6.5.2.2.3 TARE Market, By Product
- 6.5.2.2.3.1 TARE Embolic Agents Market, by Type
- 6.5.2.2.3.2 TARE Support Devices Market, by Type
- 6.5.2.2.1 TAE Market, By Product
- 6.5.2.3 By indication
- 6.5.2.3.1 Embolotherapy market for cancer, by type
- 6.5.2.3.2 Liver Cancer Embolotherapy Market, By Product
- 6.5.2.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 6.5.2.3.3 Kidney Cancer Embolotherapy Market, By Product
- 6.5.2.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 6.5.2.3.4 Other Cancer Embolotherapy Market, By Product
- 6.5.2.3.4.1 Other Cancer Embolic Agents Market, by Type
- 6.5.2.3.5 Embolotherapy market for neurological diseases, by type
- 6.5.2.4 By end user
Chapter 7. Europe Market Size and Forecast
- 7.1 By Product
7.1.1 Embolic Agents Market, by Type
7.1.2 Embolotherapy Support Devices Market, by Type
- 7.2 By Procedure
7.2.1 TAE Market, By Product
- 7.2.1.1 TAE Embolic Agents Market, by Type
- 7.2.1.2 TAE Support Devices Market, by Type
7.2.2 TACE Market, By Product
- 7.2.2.1 TACE Embolic Agents Market, by Type
- 7.2.2.2 TACE Support Devices Market, by Type
7.2.3 TARE Market, By Product
- 7.2.3.1 TARE Embolic Agents Market, by Type
- 7.2.3.2 TARE Support Devices Market, by Type
- 7.3 By Indication
7.3.1 Embolotherapy Market for Cancer, by Type
- 7.3.1.1 Liver Cancer Embolotherapy Market, By Product
- 7.3.1.1.1 Liver Cancer Embolic Agents Market, by Type
- 7.3.1.2 Kidney Cancer Embolotherapy Market, By Product
- 7.3.1.2.1 Kidney Cancer Embolic Agents Market, by Type
- 7.3.1.3 Other Cancer Embolotherapy Market, By Product
- 7.3.1.3.1 Other Cancer Embolic Agents Market, by Type
7.3.2 Embolotherapy Market for Neurological Diseases, by Type
- 7.4 By End User
- 7.5 By Country
7.5.1 Germany Market Size and Forecast
- 7.5.1.1 By product
- 7.5.1.1.1 Embolic agents market, by type
- 7.5.1.1.2 Embolotherapy support devices market, by type
- 7.5.1.2 By procedure
- 7.5.1.2.1 TAE Market, By Product
- 7.5.1.2.1.1 TAE Embolic Agents Market, by Type
- 7.5.1.2.1.2 TAE Support Devices Market, by Type
- 7.5.1.2.2 TACE Market, By Product
- 7.5.1.2.2.1 TACE Embolic Agents Market, by Type
- 7.5.1.2.2.2 TACE Support Devices Market, by Type
- 7.5.1.2.3 TARE Market, By Product
- 7.5.1.2.3.1 TARE Embolic Agents Market, by Type
- 7.5.1.2.3.2 TARE Support Devices Market, by Type
- 7.5.1.2.1 TAE Market, By Product
- 7.5.1.3 By indication
- 7.5.1.3.1 Embolotherapy market for cancer, by type
- 7.5.1.3.2 Liver Cancer Embolotherapy Market, By Product
- 7.5.1.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 7.5.1.3.3 Kidney Cancer Embolotherapy Market, By Product
- 7.5.1.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 7.5.1.3.4 Other Cancer Embolotherapy Market, By Product
- 7.5.1.3.4.1 Other Cancer Embolic Agents Market, by Type
- 7.5.1.3.5 Embolotherapy market for neurological diseases, by type
- 7.5.1.4 By end user
7.5.2 France Market Size and Forecast
- 7.5.2.1 By product
- 7.5.2.1.1 Embolic agents market, by type
- 7.5.2.1.2 Embolotherapy support devices market, by type
- 7.5.2.2 By procedure
- 7.5.2.2.1 TAE Market, By Product
- 7.5.2.2.1.1 TAE Embolic Agents Market, by Type
- 7.5.2.2.1.2 TAE Support Devices Market, by Type
- 7.5.2.2.2 TACE Market, By Product
- 7.5.2.2.2.1 TACE Embolic Agents Market, by Type
- 7.5.2.2.2.2 TACE Support Devices Market, by Type
- 7.5.2.2.3 TARE Market, By Product
- 7.5.2.2.3.1 TARE Embolic Agents Market, by Type
- 7.5.2.2.3.2 TARE Support Devices Market, by Type
- 7.5.2.2.1 TAE Market, By Product
- 7.5.2.3 By indication
- 7.5.2.3.1 Embolotherapy market for cancer, by type
- 7.5.2.3.2 Liver Cancer Embolotherapy Market, By Product
- 7.5.2.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 7.5.2.3.3 Kidney Cancer Embolotherapy Market, By Product
- 7.5.2.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 7.5.2.3.4 Other Cancer Embolotherapy Market, By Product
- 7.5.2.3.4.1 Other Cancer Embolic Agents Market, by Type
- 7.5.2.3.5 Embolotherapy market for neurological diseases, by type
- 7.5.2.4 By end user
7.5.3 U.K. Market Size and Forecast
- 7.5.3.1 By product
- 7.5.3.1.1 Embolic agents market, by type
- 7.5.3.1.2 Embolotherapy support devices market, by type
- 7.5.3.2 By procedure
- 7.5.3.2.1 TAE Market, By Product
- 7.5.3.2.1.1 TAE Embolic Agents Market, by Type
- 7.5.3.2.1.2 TAE Support Devices Market, by Type
- 7.5.3.2.2 TACE Market, By Product
- 7.5.3.2.2.1 TACE Embolic Agents Market, by Type
- 7.5.3.2.2.2 TACE Support Devices Market, by Type
- 7.5.3.2.3 TARE Market, By Product
- 7.5.3.2.3.1 TARE Embolic Agents Market, by Type
- 7.5.3.2.3.2 TARE Support Devices Market, by Type
- 7.5.3.2.1 TAE Market, By Product
- 7.5.3.3 By indication
- 7.5.3.3.1 Embolotherapy market for cancer, by type
- 7.5.3.3.2 Liver Cancer Embolotherapy Market, By Product
- 7.5.3.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 7.5.3.3.3 Kidney Cancer Embolotherapy Market, By Product
- 7.5.3.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 7.5.3.3.4 Other Cancer Embolotherapy Market, By Product
- 7.5.3.3.4.1 Other Cancer Embolic Agents Market, by Type
- 7.5.3.3.5 Embolotherapy market for neurological diseases, by type
- 7.5.3.4 By end user
7.5.4 Italy Market Size and Forecast
- 7.5.4.1 By product
- 7.5.4.1.1 Embolic agents market, by type
- 7.5.4.1.2 Embolotherapy support devices market, by type
- 7.5.4.2 By procedure
- 7.5.4.2.1 TAE Market, By Product
- 7.5.4.2.1.1 TAE Embolic Agents Market, by Type
- 7.5.4.2.1.2 TAE Support Devices Market, by Type
- 7.5.4.2.2 TACE Market, By Product
- 7.5.4.2.2.1 TACE Embolic Agents Market, by Type
- 7.5.4.2.2.2 TACE Support Devices Market, by Type
- 7.5.4.2.3 TARE Market, By Product
- 7.5.4.2.3.1 TARE Embolic Agents Market, by Type
- 7.5.4.2.3.2 TARE Support Devices Market, by Type
- 7.5.4.2.1 TAE Market, By Product
- 7.5.4.3 By indication
- 7.5.4.3.1 Embolotherapy market for cancer, by type
- 7.5.4.3.2 Liver Cancer Embolotherapy Market, By Product
- 7.5.4.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 7.5.4.3.3 Kidney Cancer Embolotherapy Market, By Product
- 7.5.4.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 7.5.4.3.4 Other Cancer Embolotherapy Market, By Product
- 7.5.4.3.4.1 Other Cancer Embolic Agents Market, by Type
- 7.5.4.3.5 Embolotherapy market for neurological diseases, by type
- 7.5.4.4 By end user
7.5.5 Spain Market Size and Forecast
- 7.5.5.1 By product
- 7.5.5.1.1 Embolic agents market, by type
- 7.5.5.1.2 Embolotherapy support devices market, by type
- 7.5.5.2 By procedure
- 7.5.5.2.1 TAE Market, By Product
- 7.5.5.2.1.1 TAE Embolic Agents Market, by Type
- 7.5.5.2.1.2 TAE Support Devices Market, by Type
- 7.5.5.2.2 TACE Market, By Product
- 7.5.5.2.2.1 TACE Embolic Agents Market, by Type
- 7.5.5.2.2.2 TACE Support Devices Market, by Type
- 7.5.5.2.3 TARE Market, By Product
- 7.5.5.2.3.1 TARE Embolic Agents Market, by Type
- 7.5.5.2.3.2 TARE Support Devices Market, by Type
- 7.5.5.2.1 TAE Market, By Product
- 7.5.5.3 By indication
- 7.5.5.3.1 Embolotherapy market for cancer, by type
- 7.5.5.3.2 Liver Cancer Embolotherapy Market, By Product
- 7.5.5.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 7.5.5.3.3 Kidney Cancer Embolotherapy Market, By Product
- 7.5.5.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 7.5.5.3.4 Other Cancer Embolotherapy Market, By Product
- 7.5.5.3.4.1 Other Cancer Embolic Agents Market, by Type
- 7.5.5.3.5 Embolotherapy market for neurological diseases, by type
- 7.5.5.4 By end user
Chapter 8. APAC Market Size and Forecast
- 8.1 By Product
8.1.1 Embolic Agents Market, by Type
8.1.2 Embolotherapy Support Devices Market, by Type
- 8.2 By Procedure
8.2.1 TAE Market, By Product
- 8.2.1.1 TAE Embolic Agents Market, by Type
- 8.2.1.2 TAE Support Devices Market, by Type
8.2.2 TACE Market, By Product
- 8.2.2.1 TACE Embolic Agents Market, by Type
- 8.2.2.2 TACE Support Devices Market, by Type
8.2.3 TARE Market, By Product
- 8.2.3.1 TARE Embolic Agents Market, by Type
- 8.2.3.2 TARE Support Devices Market, by Type
- 8.3 By Indication
8.3.1 Embolotherapy Market for Cancer, by Type
- 8.3.1.1 Liver Cancer Embolotherapy Market, By Product
- 8.3.1.1.1 Liver Cancer Embolic Agents Market, by Type
- 8.3.1.2 Kidney Cancer Embolotherapy Market, By Product
- 8.3.1.2.1 Kidney Cancer Embolic Agents Market, by Type
- 8.3.1.3 Other Cancer Embolotherapy Market, By Product
- 8.3.1.3.1 Other Cancer Embolic Agents Market, by Type
8.3.2 Embolotherapy Market for Neurological Diseases, by Type
- 8.4 By End User
- 8.5 By Country
8.5.1 China Market Size and Forecast
- 8.5.1.1 By product
- 8.5.1.1.1 Embolic agents market, by type
- 8.5.1.1.2 Embolotherapy support devices market, by type
- 8.5.1.2 By procedure
- 8.5.1.2.1 TAE Market, By Product
- 8.5.1.2.1.1 TAE Embolic Agents Market, by Type
- 8.5.1.2.1.2 TAE Support Devices Market, by Type
- 8.5.1.2.2 TACE Market, By Product
- 8.5.1.2.2.1 TACE Embolic Agents Market, by Type
- 8.5.1.2.2.2 TACE Support Devices Market, by Type
- 8.5.1.2.3 TARE Market, By Product
- 8.5.1.2.3.1 TARE Embolic Agents Market, by Type
- 8.5.1.2.3.2 TARE Support Devices Market, by Type
- 8.5.1.2.1 TAE Market, By Product
- 8.5.1.3 By indication
- 8.5.1.3.1 Embolotherapy market for cancer, by type
- 8.5.1.3.2 Liver Cancer Embolotherapy Market, By Product
- 8.5.1.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 8.5.1.3.3 Kidney Cancer Embolotherapy Market, By Product
- 8.5.1.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 8.5.1.3.4 Other Cancer Embolotherapy Market, By Product
- 8.5.1.3.4.1 Other Cancer Embolic Agents Market, by Type
- 8.5.1.3.5 Embolotherapy market for neurological diseases, by type
- 8.5.1.4 By end user
8.5.2 Japan Market Size and Forecast
- 8.5.2.1 By product
- 8.5.2.1.1 Embolic agents market, by type
- 8.5.2.1.2 Embolotherapy support devices market, by type
- 8.5.2.2 By procedure
- 8.5.2.2.1 TAE Market, By Product
- 8.5.2.2.1.1 TAE Embolic Agents Market, by Type
- 8.5.2.2.1.2 TAE Support Devices Market, by Type
- 8.5.2.2.2 TACE Market, By Product
- 8.5.2.2.2.1 TACE Embolic Agents Market, by Type
- 8.5.2.2.2.2 TACE Support Devices Market, by Type
- 8.5.2.2.3 TARE Market, By Product
- 8.5.2.2.3.1 TARE Embolic Agents Market, by Type
- 8.5.2.2.3.2 TARE Support Devices Market, by Type
- 8.5.2.2.1 TAE Market, By Product
- 8.5.2.3 By indication
- 8.5.2.3.1 Embolotherapy market for cancer, by type
- 8.5.2.3.2 Liver Cancer Embolotherapy Market, By Product
- 8.5.2.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 8.5.2.3.3 Kidney Cancer Embolotherapy Market, By Product
- 8.5.2.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 8.5.2.3.4 Other Cancer Embolotherapy Market, By Product
- 8.5.2.3.4.1 Other Cancer Embolic Agents Market, by Type
- 8.5.2.3.5 Embolotherapy market for neurological diseases, by type
- 8.5.2.4 By end user
8.5.3 India Market Size and Forecast
- 8.5.3.1 By product
- 8.5.3.1.1 Embolic agents market, by type
- 8.5.3.1.2 Embolotherapy support devices market, by type
- 8.5.3.2 By procedure
- 8.5.3.2.1 TAE Market, By Product
- 8.5.3.2.1.1 TAE Embolic Agents Market, by Type
- 8.5.3.2.1.2 TAE Support Devices Market, by Type
- 8.5.3.2.2 TACE Market, By Product
- 8.5.3.2.2.1 TACE Embolic Agents Market, by Type
- 8.5.3.2.2.2 TACE Support Devices Market, by Type
- 8.5.3.2.3 TARE Market, By Product
- 8.5.3.2.3.1 TARE Embolic Agents Market, by Type
- 8.5.3.2.3.2 TARE Support Devices Market, by Type
- 8.5.3.2.1 TAE Market, By Product
- 8.5.3.3 By indication
- 8.5.3.3.1 Embolotherapy market for cancer, by type
- 8.5.3.3.2 Liver Cancer Embolotherapy Market, By Product
- 8.5.3.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 8.5.3.3.3 Kidney Cancer Embolotherapy Market, By Product
- 8.5.3.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 8.5.3.3.4 Other Cancer Embolotherapy Market, By Product
- 8.5.3.3.4.1 Other Cancer Embolic Agents Market, by Type
- 8.5.3.3.5 Embolotherapy market for neurological diseases, by type
- 8.5.3.4 By end user
8.5.4 South Korea Market Size and Forecast
- 8.5.4.1 By product
- 8.5.4.1.1 Embolic agents market, by type
- 8.5.4.1.2 Embolotherapy support devices market, by type
- 8.5.4.2 By procedure
- 8.5.4.2.1 TAE Market, By Product
- 8.5.4.2.1.1 TAE Embolic Agents Market, by Type
- 8.5.4.2.1.2 TAE Support Devices Market, by Type
- 8.5.4.2.2 TACE Market, By Product
- 8.5.4.2.2.1 TACE Embolic Agents Market, by Type
- 8.5.4.2.2.2 TACE Support Devices Market, by Type
- 8.5.4.2.3 TARE Market, By Product
- 8.5.4.2.3.1 TARE Embolic Agents Market, by Type
- 8.5.4.2.3.2 TARE Support Devices Market, by Type
- 8.5.4.2.1 TAE Market, By Product
- 8.5.4.3 By indication
- 8.5.4.3.1 Embolotherapy market for cancer, by type
- 8.5.4.3.2 Liver Cancer Embolotherapy Market, By Product
- 8.5.4.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 8.5.4.3.3 Kidney Cancer Embolotherapy Market, By Product
- 8.5.4.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 8.5.4.3.4 Other Cancer Embolotherapy Market, By Product
- 8.5.4.3.4.1 Other Cancer Embolic Agents Market, by Type
- 8.5.4.3.5 Embolotherapy market for neurological diseases, by type
- 8.5.4.4 By end user
8.5.5 Singapore Market Size and Forecast
- 8.5.5.1 By product
- 8.5.5.1.1 Embolic agents market, by type
- 8.5.5.1.2 Embolotherapy support devices market, by type
- 8.5.5.2 By procedure
- 8.5.5.2.1 TAE Market, By Product
- 8.5.5.2.1.1 TAE Embolic Agents Market, by Type
- 8.5.5.2.1.2 TAE Support Devices Market, by Type
- 8.5.5.2.2 TACE Market, By Product
- 8.5.5.2.2.1 TACE Embolic Agents Market, by Type
- 8.5.5.2.2.2 TACE Support Devices Market, by Type
- 8.5.5.2.3 TARE Market, By Product
- 8.5.5.2.3.1 TARE Embolic Agents Market, by Type
- 8.5.5.2.3.2 TARE Support Devices Market, by Type
- 8.5.5.2.1 TAE Market, By Product
- 8.5.5.3 By indication
- 8.5.5.3.1 Embolotherapy market for cancer, by type
- 8.5.5.3.2 Liver Cancer Embolotherapy Market, By Product
- 8.5.5.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 8.5.5.3.3 Kidney Cancer Embolotherapy Market, By Product
- 8.5.5.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 8.5.5.3.4 Other Cancer Embolotherapy Market, By Product
- 8.5.5.3.4.1 Other Cancer Embolic Agents Market, by Type
- 8.5.5.3.5 Embolotherapy market for neurological diseases, by type
- 8.5.5.4 By end user
Chapter 9. LATAM Market Size and Forecast
- 9.1 By Product
9.1.1 Embolic Agents Market, by Type
9.1.2 Embolotherapy Support Devices Market, by Type
- 9.2 By Procedure
9.2.1 TAE Market, By Product
- 9.2.1.1 TAE Embolic Agents Market, by Type
- 9.2.1.2 TAE Support Devices Market, by Type
9.2.2 TACE Market, By Product
- 9.2.2.1 TACE Embolic Agents Market, by Type
- 9.2.2.2 TACE Support Devices Market, by Type
9.2.3 TARE Market, By Product
- 9.2.3.1 TARE Embolic Agents Market, by Type
- 9.2.3.2 TARE Support Devices Market, by Type
- 9.3 By Indication
9.3.1 Embolotherapy Market for Cancer, by Type
- 9.3.1.1 Liver Cancer Embolotherapy Market, By Product
- 9.3.1.1.1 Liver Cancer Embolic Agents Market, by Type
- 9.3.1.2 Kidney Cancer Embolotherapy Market, By Product
- 9.3.1.2.1 Kidney Cancer Embolic Agents Market, by Type
- 9.3.1.3 Other Cancer Embolotherapy Market, By Product
- 9.3.1.3.1 Other Cancer Embolic Agents Market, by Type
9.3.2 Embolotherapy Market for Neurological Diseases, by Type
- 9.4 By End User
- 9.5 By Country
9.5.1 Brazil Market Size and Forecast
- 9.5.1.1 By product
- 9.5.1.1.1 Embolic agents market, by type
- 9.5.1.1.2 Embolotherapy support devices market, by type
- 9.5.1.2 By procedure
- 9.5.1.2.1 TAE Market, By Product
- 9.5.1.2.1.1 TAE Embolic Agents Market, by Type
- 9.5.1.2.1.2 TAE Support Devices Market, by Type
- 9.5.1.2.2 TACE Market, By Product
- 9.5.1.2.2.1 TACE Embolic Agents Market, by Type
- 9.5.1.2.2.2 TACE Support Devices Market, by Type
- 9.5.1.2.3 TARE Market, By Product
- 9.5.1.2.3.1 TARE Embolic Agents Market, by Type
- 9.5.1.2.3.2 TARE Support Devices Market, by Type
- 9.5.1.2.1 TAE Market, By Product
- 9.5.1.3 By indication
- 9.5.1.3.1 Embolotherapy market for cancer, by type
- 9.5.1.3.2 Liver Cancer Embolotherapy Market, By Product
- 9.5.1.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 9.5.1.3.3 Kidney Cancer Embolotherapy Market, By Product
- 9.5.1.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 9.5.1.3.4 Other Cancer Embolotherapy Market, By Product
- 9.5.1.3.4.1 Other Cancer Embolic Agents Market, by Type
- 9.5.1.3.5 Embolotherapy market for neurological diseases, by type
- 9.5.1.4 By end user
9.5.2 Mexico Market Size and Forecast
- 9.5.2.1 By product
- 9.5.2.1.1 Embolic agents market, by type
- 9.5.2.1.2 Embolotherapy support devices market, by type
- 9.5.2.2 By procedure
- 9.5.2.2.1 TAE Market, By Product
- 9.5.2.2.1.1 TAE Embolic Agents Market, by Type
- 9.5.2.2.1.2 TAE Support Devices Market, by Type
- 9.5.2.2.2 TACE Market, By Product
- 9.5.2.2.2.1 TACE Embolic Agents Market, by Type
- 9.5.2.2.2.2 TACE Support Devices Market, by Type
- 9.5.2.2.3 TARE Market, By Product
- 9.5.2.2.3.1 TARE Embolic Agents Market, by Type
- 9.5.2.2.3.2 TARE Support Devices Market, by Type
- 9.5.2.2.1 TAE Market, By Product
- 9.5.2.3 By indication
- 9.5.2.3.1 Embolotherapy market for cancer, by type
- 9.5.2.3.2 Liver Cancer Embolotherapy Market, By Product
- 9.5.2.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 9.5.2.3.3 Kidney Cancer Embolotherapy Market, By Product
- 9.5.2.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 9.5.2.3.4 Other Cancer Embolotherapy Market, By Product
- 9.5.2.3.4.1 Other Cancer Embolic Agents Market, by Type
- 9.5.2.3.5 Embolotherapy market for neurological diseases, by type
- 9.5.2.4 By end user
Chapter 10. MEA Market Size and Forecast
- 10.1 By Product
10.1.1 Embolic Agents Market, by Type
10.1.2 Embolotherapy Support Devices Market, by Type
- 10.2 By Procedure
10.2.1 TAE Market, By Product
- 10.2.1.1 TAE Embolic Agents Market, by Type
- 10.2.1.2 TAE Support Devices Market, by Type
10.2.2 TACE Market, By Product
- 10.2.2.1 TACE Embolic Agents Market, by Type
- 10.2.2.2 TACE Support Devices Market, by Type
10.2.3 TARE Market, By Product
- 10.2.3.1 TARE Embolic Agents Market, by Type
- 10.2.3.2 TARE Support Devices Market, by Type
- 10.3 By Indication
10.3.1 Embolotherapy Market for Cancer, by Type
- 10.3.1.1 Liver Cancer Embolotherapy Market, By Product
- 10.3.1.1.1 Liver Cancer Embolic Agents Market, by Type
- 10.3.1.2 Kidney Cancer Embolotherapy Market, By Product
- 10.3.1.2.1 Kidney Cancer Embolic Agents Market, by Type
- 10.3.1.3 Other Cancer Embolotherapy Market, By Product
- 10.3.1.3.1 Other Cancer Embolic Agents Market, by Type
10.3.2 Embolotherapy Market for Neurological Diseases, by Type
- 10.4 By End User
- 10.5 By Country
10.5.1 Saudi Arabia Market Size and Forecast
- 10.5.1.1 By product
- 10.5.1.1.1 Embolic agents market, by type
- 10.5.1.1.2 Embolotherapy support devices market, by type
- 10.5.1.2 By procedure
- 10.5.1.2.1 TAE Market, By Product
- 10.5.1.2.1.1 TAE Embolic Agents Market, by Type
- 10.5.1.2.1.2 TAE Support Devices Market, by Type
- 10.5.1.2.2 TACE Market, By Product
- 10.5.1.2.2.1 TACE Embolic Agents Market, by Type
- 10.5.1.2.2.2 TACE Support Devices Market, by Type
- 10.5.1.2.3 TARE Market, By Product
- 10.5.1.2.3.1 TARE Embolic Agents Market, by Type
- 10.5.1.2.3.2 TARE Support Devices Market, by Type
- 10.5.1.2.1 TAE Market, By Product
- 10.5.1.3 By indication
- 10.5.1.3.1 Embolotherapy market for cancer, by type
- 10.5.1.3.2 Liver Cancer Embolotherapy Market, By Product
- 10.5.1.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 10.5.1.3.3 Kidney Cancer Embolotherapy Market, By Product
- 10.5.1.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 10.5.1.3.4 Other Cancer Embolotherapy Market, By Product
- 10.5.1.3.4.1 Other Cancer Embolic Agents Market, by Type
- 10.5.1.3.5 Embolotherapy market for neurological diseases, by type
- 10.5.1.4 By end user
10.5.2 South Africa Market Size and Forecast
- 10.5.2.1 By product
- 10.5.2.1.1 Embolic agents market, by type
- 10.5.2.1.2 Embolotherapy support devices market, by type
- 10.5.2.2 By procedure
- 10.5.2.2.1 TAE Market, By Product
- 10.5.2.2.1.1 TAE Embolic Agents Market, by Type
- 10.5.2.2.1.2 TAE Support Devices Market, by Type
- 10.5.2.2.2 TACE Market, By Product
- 10.5.2.2.2.1 TACE Embolic Agents Market, by Type
- 10.5.2.2.2.2 TACE Support Devices Market, by Type
- 10.5.2.2.3 TARE Market, By Product
- 10.5.2.2.3.1 TARE Embolic Agents Market, by Type
- 10.5.2.2.3.2 TARE Support Devices Market, by Type
- 10.5.2.2.1 TAE Market, By Product
- 10.5.2.3 By indication
- 10.5.2.3.1 Embolotherapy market for cancer, by type
- 10.5.2.3.2 Liver Cancer Embolotherapy Market, By Product
- 10.5.2.3.2.1 Liver Cancer Embolic Agents Market, by Type
- 10.5.2.3.3 Kidney Cancer Embolotherapy Market, By Product
- 10.5.2.3.3.1 Kidney Cancer Embolic Agents Market, by Type
- 10.5.2.3.4 Other Cancer Embolotherapy Market, By Product
- 10.5.2.3.4.1 Other Cancer Embolic Agents Market, by Type
- 10.5.2.3.5 Embolotherapy market for neurological diseases, by type
- 10.5.2.4 By end user
Chapter 11. Competitive Landscape
- 11.1 List of Key Players
- 11.2 Strategic Developments of Key Players
11.2.1 Product Launches & Approvals
11.2.2 Partnerships and Collaborations
11.2.3 Mergers and Acquisitions
11.2.4 Facility and Geographical Expansions
11.2.5 Investments and Funding
11.2.6 Other Developments
Chapter 12. Company Profiles
- 12.1 Stryker Corporation
12.1.1 Business Overview
12.1.2 Product and Service Offerings
12.1.3 Key Financial Summary
- 12.2 Sirtex Medical Pty Ltd.
12.2.1 Business Overview
12.2.2 Product and Service Offerings
- 12.3 Merit Medical Systems Inc.
12.3.1 Business Overview
12.3.2 Product and Service Offerings
12.3.3 Key Financial Summary
- 12.4 Meril Life Sciences Pvt. Ltd.
12.4.1 Business Overview
12.4.2 Product and Service Offerings
- 12.5 Acandis GmbH
12.5.1 Business Overview
12.5.2 Product and Service Offerings
- 12.6 BALT Group
12.6.1 Business Overview
12.6.2 Product and Service Offerings
- 12.7 Medtronic plc
12.7.1 Business Overview
12.7.2 Product and Service Offerings
12.7.3 Key Financial Summary
- 12.8 Kaneka Corporation
12.8.1 Business Overview
12.8.2 Product and Service Offerings
12.8.3 Key Financial Summary
- 12.9 Guerbet S.A.
12.9.1 Business Overview
12.9.2 Product and Service Offerings
12.9.3 Key Financial Summary
- 12.10 Terumo Corporation
12.10.1 Business Overview
12.10.2 Product and Service Offerings
12.10.3 Key Financial Summary
- 12.11 Boston Scientific Corporation
12.11.1 Business Overview
12.11.2 Product and Service Offerings
12.11.3 Key Financial Summary
- 12.12 Abbott Laboratories
12.12.1 Business Overview
12.12.2 Product and Service Offerings
12.12.3 Key Financial Summary
- 12.13 Johnson & Johnson
12.13.1 Business Overview
12.13.2 Product and Service Offerings
12.13.3 Key Financial Summary
- 12.14 Shape Memory Medical Inc.
12.14.1 Business Overview
12.14.2 Product and Service Offerings
- 12.15 Rapid Medical Ltd.
12.15.1 Business Overview
12.15.2 Product and Service Offerings
- 12.16 IMBiotechnologies Ltd.
12.16.1 Business Overview
12.16.2 Product and Service Offerings
- 12.17 COOK MEDICAL LLC
12.17.1 Business Overview
12.17.2 Product and Service Offerings
- 12.18 ABK Biomedical Inc.
12.18.1 Business Overview
12.18.2 Product and Service Offerings
- 12.19 Penumbra Inc.
12.19.1 Business Overview
12.19.2 Product and Service Offerings
12.19.3 Key Financial Summary
- 12.20 Peijia Medical Limited
12.20.1 Business Overview
12.20.2 Product and Service Offerings
12.20.3 Key Financial Summary
- 12.21 Varian Medical Systems Inc
12.21.1 Business Overview
12.21.2 Product and Service Offerings
- 12.22 MicroPort Scientific Corporation
12.22.1 Business Overview
12.22.2 Product and Service Offerings
12.22.3 Key Financial Summary
- 12.23 Shandong Visee Medical Devices Co. Ltd.
12.23.1 Business Overview
12.23.2 Product and Service Offerings
Chapter 13. Appendix
- 13.1 Sources and References
- 13.2 Related Reports
List of Tables
- TABLE 1 ANALYSIS PERIOD OF THE STUDY
- TABLE 2 Drivers for The Market: Impact Analysis
- TABLE 3 Restraints for The Market: Impact Analysis
- TABLE 4 Global Embolotherapy market, by product, $M (2017-2024)
- TABLE 5 Global Embolotherapy market, by product, $M (2025-2030)
- TABLE 6 global Embolic Agents Market, BY TYPE, $M (2017-2024)
- TABLE 7 global Embolic Agents Market, by type, $M (2025-2030)
- TABLE 8 Global Embolotherapy Support Devices market, by Type, $M (2017-2024)
- TABLE 9 Global Embolotherapy Support Devices market, by Type, $M (2025-2030)
- TABLE 10 Global Embolotherapy market, by procedure, $M (2017-2024)
- TABLE 11 Global Embolotherapy market, by procedure, $M (2025-2030)
- TABLE 12 Global tae Embolotherapy market, by product, $M (2017-2024)
- TABLE 13 Global tae Embolotherapy market, by product, $M (2025-2030)
- TABLE 14 global tae Embolic Agents Market, BY TYPE, $M (2017-2024)
- TABLE 15 global tae Embolic Agents Market, by type, $M (2025-2030)
- TABLE 16 Global TAE Support Devices market, by Type, $M (2017-2024)
- TABLE 17 Global TAE Support Devices market, by Type, $M (2025-2030)
- TABLE 18 Global TACE Embolotherapy market, by product, $M (2017-2024)
- TABLE 19 Global TACE Embolotherapy market, by product, $M (2025-2030)
- TABLE 20 global TACE Embolic Agents Market, BY TYPE, $M (2017-2024)
- TABLE 21 global TACE Embolic Agents Market, by type, $M (2025-2030)
- TABLE 22 Global TACE Support Devices market, by Type, $M (2017-2024)
- TABLE 23 Global TACE Support Devices market, by Type, $M (2025-2030)
- TABLE 24 Global tare Embolotherapy market, by product, $M (2017-2024)
- TABLE 25 Global tare Embolotherapy market, by product, $M (2025-2030)
- TABLE 26 global TARE Embolic Agents Market, BY TYPE, $M (2017-2024)
- TABLE 27 global TARE Embolic Agents Market, by type, $M (2025-2030)
- TABLE 28 Global TARE Support Devices market, by Type, $M (2017-2024)
- TABLE 29 Global TARE Support Devices market, by Type, $M (2025-2030)
- TABLE 30 Global Embolotherapy market, by indication, $M (2017-2024)
- TABLE 31 Global Embolotherapy market, by indication, $M (2025-2030)
- TABLE 32 Global Embolotherapy Market for Cancer, BY TYPE, $M (2017-2024)
- TABLE 33 Global Embolotherapy Market for Cancer, BY TYPE, $M (2025-2030)
- TABLE 34 Global liver Cancer Embolotherapy market, by product, $M (2017-2024)
- TABLE 35 Global liver Cancer Embolotherapy market, by product, $M (2025-2030)
- TABLE 36 global liver Cancer Embolic Agents Market, BY TYPE, $M (2017-2024)
- TABLE 37 global liver Cancer Embolic Agents Market, by type, $M (2025-2030)
- TABLE 38 Global kidney Cancer Embolotherapy market, by product, $M (2017-2024)
- TABLE 39 Global kidney Cancer Embolotherapy market, by product, $M (2025-2030)
- TABLE 40 global Kidney Cancer Embolic Agents Market, BY TYPE, $M (2017-2024)
- TABLE 41 global Kidney Cancer Embolic Agents Market, by type, $M (2025-2030)
- TABLE 42 Global Other Cancer Embolotherapy market, by product, $M (2017-2024)
- TABLE 43 Global Other Cancer Embolotherapy market, by product, $M (2025-2030)
- TABLE 44 global Other Cancer Embolic Agents Market, BY TYPE, $M (2017-2024)
- TABLE 45 global Other Cancer Embolic Agents Market, by type, $M (2025-2030)
- TABLE 46 Global Embolotherapy Market for Neurological Diseases, BY TYPE, $M (2017-2024)
- TABLE 47 Global Embolotherapy Market for Neurological Diseases, BY TYPE, $M (2025-2030)
- TABLE 48 Global Embolotherapy Market, BY end user, $M (2017-2024)
- TABLE 49 Global Embolotherapy Market, BY end user, $M (2025-2030)
- TABLE 50 global Embolotherapy market, by region, $M (2017-2024)
- TABL
